| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
32 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-58 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Synthorx, Inc. is a biotechnology company that specializes in the development of novel synthetic biology platforms for the creation of new therapeutics. The company was founded in 2014 and is headquartered in La Jolla, California.
The core technology of Synthorx, Inc. is based on expanding the genetic alphabet beyond the natural four nucleotides, adenine (A), cytosine (C), guanine (G), and thymine (T), to include synthetic nucleotides known as xenobiotics. This unique technology is known as Synthorin and enables the creation of novel proteins with enhanced properties, stability, and efficacy.
With this technology, Synthorx, Inc. is developing a diverse pipeline of therapeutics that address unmet medical needs in several therapeutic areas, such as immuno-oncology, autoimmune, and genetic disorders. The company's lead product candidate, THOR-707, which is being developed as an immuno-oncology therapy, is a fusion protein designed to selectively stimulate and expand the activity of T cells, the immune cells responsible for killing cancer cells.
Synthorx, Inc. employs a multi-disciplinary team of scientists with expertise in protein engineering, immunology, synthetic biology, and molecular biology. The company has also formed collaborations with other biotech and pharmaceutical companies to accelerate the discovery and development of new therapeutics.
In 2018, Synthorx, Inc. went public, raising $131 million in its initial public offering. The company has continued to expand its pipeline, announcing several new programs in 2020 and 2021, including synthetic cytokines and novel gene therapies.
Overall, Synthorx, Inc. is poised to make significant contributions to the development of new therapeutics using its innovative synthetic biology platform. Its team of experts, unique technology, and strong collaborations make it a promising company to watch in the biotechnology space.
Company Address: 11099 N. Torrey Pines Road La Jolla 92037 CA
Company Phone Number: 750-4789 Stock Exchange / Ticker: NASDAQ THOR
|
%